Badger Meter Inc vs Cronos Group Inc — how do they compare? Badger Meter Inc trades at $132.67 (market cap $3.93B), while Cronos Group Inc trades at $3.08 (market cap $1.14B). The key difference: Badger Meter Inc is far larger — about 3.4× Cronos Group Inc's market cap, and Badger Meter Inc pays a 1.18% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| BMI | CRON | |
|---|---|---|
Market Cap | $3.93B | $1.14B |
Sector | Technology | Health |
52-Week High | $193.09 | $3.27 |
52-Week Low | $113.41 | $2.30 |
Enterprise Value | $3.84B | $341.13M |
Dividend Yield | 1.18% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CRON trades at $3.00, down 3.23% today, with a bullish technical signal from moving averages. The company showed strong Q2 2026 performance with 58% YoY revenue growth and earnings beat, though recent quarters were mixed. Valuation metrics include P/E of 16.21 and P/S of 6.55, while profitability improved with 45.86% gross margin. Analyst consensus is mixed with 20% buy, 60% hold ratings.
Outlook remains positive due to international expansion and strong product positioning, particularly in Canada and Europe. Key risks include competitive pressures and cash flow volatility from aggressive investing. The stock presents growth potential but requires monitoring of execution and market conditions.
Trailing returns across standard periods
Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.
Read more on BMI →Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →